C difficile Toxins A+B, EIA

Negative
Negative test results for both the bacteria and the toxin may mean that the diarrhea and other symptoms are being caused by something other than C. difficile. Since the toxin breaks down at room temperature within two hours, a negative result may also indicate that the sample was not transported, stored, or processed promptly. If there is a concern that a stool specimen has not been collected and processed properly, a second specimen may be submitted for testing after discussion with the laboratory.
Positive
If tests for C. difficile toxin gene and C. difficile toxin are positive, it is likely that the person's diarrhea and related symptoms are due to the presence of toxin-producing C. difficile. A positive result for C. difficile bacteria or C. difficile antigen (GDH) but a negative C. difficile toxin result means that the bacteria are present in the digestive tract but are not producing a detectable level of toxin. If a person has positive C. difficile test results, the healthcare practitioner will typically discontinue any antibiotics that the person is taking and prescribe an appropriate treatment of oral antibiotic, such as vancomycin or fidaxomicin, to eliminate the C. difficile bacteria. Recently, so-called stool transplants have been investigated as an effective treatment for people with recurrent C. difficile infections. An endoscopic procedure can be used to diagnose C. difficile colitis. A specialist (gastroenterologist) can examine the colon and biopsy any characteristic pseudomembranous lesions that may be present.

Doctors often suspect C. difficile in anyone who has diarrhea and who has other risk factors for C. difficile. 

Clostridium difficile (klos-TRID-e-um dif-uh-SEEL), also known as Clostridioides difficile and often referred to as C. difficile or C. diff, is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon.

Illness from C. difficile most commonly affects older adults in hospitals or in long-term care facilities and typically occurs after use of antibiotic medications. However, studies show increasing rates of C. difficile infection among people traditionally not considered to be at high risk, such as young and healthy individuals who haven't used antibiotics and who haven't been in a health care facility.

Each year in the United States, about a half million people get sick from C. difficile, and in recent years, C. difficile infections have become more frequent, severe and difficult to treat. Recurrent C. difficile infections also are on the rise.

C difficile can produce two toxins, designated A and B, that have pathogenic effects in humans. Antibiotic-associated pseudomembranous colitis has been shown to result from the action of these two toxins. This disease has been associated with clindamycin use but it is now recognized that pseudomembranous colitis can follow administration of virtually any antibiotic. More than 70 percent of the cases in a large series were associated with cephalosporin therapy. The clinical spectrum of antibiotic-induced syndromes caused by C difficile includes patients with symptoms of acute abdomen with little or no diarrhea, as well as cases with fulminant life-threatening diarrhea. Nosocomial transmission and reinfection with different strains occurs as do spontaneous cases without prior antimicrobial therapy. In cases where cessation of antibiotic therapy does not produce a response, specific therapy with oral vancomycin, metronidazole, or oral bacitracin may be effective. Detection of the toxins produced by C difficile (rather than culture of the organism) is important in the determining therapy of this potentially fatal disease.

EIA:

EIA stands for Enzyme immunoassay. The enzyme immunoassay (EIA) test is faster than other tests but isn't sensitive enough to detect many infections and has a higher rate of falsely normal results. For more than 20 years the detection of toxin A/B from fecal samples by immunoenzymatic methods has been the cornerstone of laboratory CDI diagnosis. Toxin enzyme immunoassays (EIAs) are more rapid and easier to perform than culture or cytotoxin assays, they do not require special equipments or a dedicated technician, and the turnaround time allows the laboratory to refer results within the same day of specimen arrival. However, the performance of immunoenzymatic kits for C. difficile toxin(s) detection available on the market versus gold-standard methods is currently considered suboptimal (both in terms of sensitivity and specificity) if used as standalone assays. 

References:

https://jcm.asm.org/content/51/3/869

C difficile Toxins A+B, EIA
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond C difficile Toxins A+B, EIA — 10,000+ markers explained
One C difficile Toxins A+B, EIA result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro